Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease

Anti-tumor necrosis factor-α (TNF) agents, including infliximab , adalimumab , and certolizumab pegol , are effective medications for the management of moderate to severe Crohn disease (CD). They are effective in inducing and maintaining clinical remission, inducing mucosal healing, improving quality of life , and reducing the risk of hospitalization and surgery in adult and pediatric patients with CD. Future research into comparative...